Hijano Diego R, Ferrolino Jose A, Swift Elizabeth G, Michaels Carolyn A, Max Anita, Hayden Randall T, Wolf Joshua, Dallas Ronald H, Greene William L, Richardson Julie L, Hakim Hana, Morton Ted H, Cross Shane J
Department of Infectious Diseases, St. Jude Children Research Hospital, Memphis, TN, United States.
Center for Advanced Practice Providers, St. Jude Children Research Hospital, Memphis, TN, United States.
Front Oncol. 2023 Aug 3;13:1229655. doi: 10.3389/fonc.2023.1229655. eCollection 2023.
From 8 December 2021 to 26 January 2023, tixagevimab-cilgavimab (T-C) was authorized for pre-exposure prophylaxis of COVID-19. During this period, we used a multidisciplinary team to communicate, screen, approach, and administer T-C to eligible patients. Twenty-seven patients were eligible. Of these, 24 (88.9%) received at least one dose of T-C and three patients received two doses. Majority of patients were White, non-Hispanic, and women. Only two patients had COVID-19 prior to receiving T-C. Seventeen (70.8%) had received two or more doses of SARS-CoV-2 vaccine. No serious adverse events were noted. Seven patients developed SARS-CoV-2 infection within 180 days of receiving T-C (median 102 days; range 28-135), and only one patient developed severe COVID-19 requiring intensive mechanical ventilation in the intensive care unit.
从2021年12月8日至2023年1月26日，替沙格韦单抗-西加韦单抗（T-C）被批准用于新型冠状病毒肺炎（COVID-19）的暴露前预防。在此期间，我们使用多学科团队对符合条件的患者进行沟通、筛查、评估并给予T-C治疗。27例患者符合条件。其中，24例（88.9%）接受了至少一剂T-C，3例患者接受了两剂。大多数患者为非西班牙裔白人女性。仅2例患者在接受T-C之前感染过COVID-19。17例（70.8%）接受过两剂或更多剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗。未观察到严重不良事件。7例患者在接受T-C后180天内发生SARS-CoV-2感染（中位时间102天；范围28-135天），仅1例患者发生严重COVID-19，需要在重症监护病房进行有创机械通气。
